IRulya Therapeutics Inc. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 19, 2026, to register up to 1,000,000 shares of common stock issuable under its newly adopted 2026 Inducement Plan.

Key Highlights

  • Shares registered: Up to 1,000,000 shares of common stock, par value $0.001 per share, are covered by the registration statement.
  • Plan adoption date: The Board of Directors adopted the 2026 Inducement Plan on November 9, 2026.
  • Purpose of the plan: Shares are reserved exclusively for equity-based awards to individuals who were not previously employees or directors of the registrant, as a material inducement to employment.
  • No stockholder approval: The Inducement Plan was adopted by the Board without stockholder approval, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Filer status: IRulya Therapeutics is classified as a non-accelerated filer and a smaller reporting company.
  • Agent for service: Brigette Roberts, Chief Executive Officer, is named as the agent for service of process.

IRulya Therapeutics Files S-8 to Cover New Hire Equity Awards Under 2026 Inducement Plan

According to the filing, IRulya Therapeutics Inc. (NASDAQ:IRLA), a Delaware corporation headquartered at 101 College Street, Suite 210, New Haven, Connecticut 06510, registered 1,000,000 shares of its common stock on Form S-8 on November 19, 2026. The registration is tied to the company's 2026 Inducement Plan, which the Board of Directors adopted on November 9, 2026, reserving those shares for equity-based awards to new hires.

The filing states that the Inducement Plan is intended to be used "exclusively for the grants of equity-based awards to individuals who were not previously employees or directors of the Registrant as a material inducement to such individual's entry into employment with the Registrant within the meaning of Rule 5635(c) of the Nasdaq Listing Rules." The Board adopted the plan without seeking stockholder approval, relying on Rule 5635(c)(4) of the Nasdaq Listing Rules, as disclosed in the registration statement.

The registration statement incorporates by reference previously filed documents, including the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed April 10, 2026; Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026; and numerous Current Reports on Form 8-K. The registrant also disclosed that it maintains insurance policies indemnifying its directors and officers against various liabilities under the Securities Act and the Exchange Act.

What Was Disclosed

IRulya Therapeutics filed a Form S-8 on November 19, 2026, registering 1,000,000 shares of common stock (par value $0.001) under its Board-approved 2026 Inducement Plan, which is reserved solely for equity awards to newly hired individuals not previously affiliated with the company.